If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
== Chemistry and animal toxicology == Buformin hydrochloride is a fine, white to slightly yellow, crystalline, odorless powder, with a weakly acidic bitter taste. Its melting point is 174 to 177 °C, it is a strong base, and is freely soluble in water, methanol and ethanol, but insoluble in chloroform and ether. The log octanol-water partition coefficient (log P) is -1.20E+00 and its water solubility is 7.46E+05 mg/L at 25 °C. Vapor pressure is 1.64E-04 mm Hg at 25 °C (EST); Henry's law constant is 8.14E-16 atm-m3/mole at 25 °C (EST). Its Atmospheric -OH rate constant is 1.60E-10 cm3/molecule-sec at 25 °C.
=== Composition === The Composition C-4 used by the United States Armed Forces contains 91% RDX ("Research Department Explosive", an explosive nitroamine), bound by a mixture of 5.3% dioctyl sebacate (DOS) or dioctyl adipate (DOA) as the plasticizer (to increase the plasticity of the explosive), thickened with 2.1% polyisobutylene (PIB, a synthetic rubber) as the binder, and 1.6% of a mineral oil often called "process oil". Instead of "process oil", low-viscosity motor oil is used in the manufacture of C-4 for civilian use. The British PE4 consists of 88.0% RDX, 1.0% pentaerythrite dioleate and 11.0% DG-29 lithium grease (corresp. to 2.2% lithium stearate and 8.8% mineral oil BP) as the binder; a taggant (2,3-dimethyl-2,3-dinitrobutane, DMDNB) is added at a minimum of 0.10% weight of the plastic explosive, typically at 1.0% mass. The newer PE7 consists of 88.0% RDX, 1.0% DMDNB taggant and 11.0% of a binder composed of low molecular mass hydroxyl-terminated polybutadiene, along with an antioxidant and an agent preventing hardening of the binder upon prolonged storage. The PE8 consists of 86.5% RDX, 1.0% DMDNB taggant and 12.5% of a binder composed of di(2-ethylhexyl) sebacate thickened with high molecular mass polyisobutylene. Technical data according to the Department of the Army for the Composition C-4 follows.
==== Food Distribution and Food Insecurity ==== Organizations that are founded to target food insecurity have relied on food distribution to serve people in need of regular nutritious foods. Food banks are the proper term to call these kind of organizations where they use "government sector, private sector, and civil society" to distribute and recover food that will ultimately go to waste. In the United States, there are many organizations all over the country that have the same similar goal however, there is not much effective collaboration between all organizations because it is challenging to coordinate efficient communication within one another. There is one large organization that focuses on distributing food to people who need it in the United States, Feeding America has over 200 food banks and 60,000 food pantries. There are more organizations that focus on distributing food that work independently and are not as big as Feeding America that contribute to distributing food to help with the issue of food insecurity.
=== Political === When the Allies achieved victory, Mexico was among the victors, despite only actively sending soldiers in the last year of the conflict. Therefore, the country was a founding member of the United Nations Organization, unlike the founding of the League of Nations in 1919, where it was not invited because it had remained neutral during the First World War. In the international arena, Mexico was more present, taking part in the Dumbarton Oaks Conference, the Treaty of San Francisco, the Bretton Woods Conference, and managed to have its initiative approved so that the dictatorship of Francisco Franco in Spain would not be recognized or admitted as a legitimate government before the UN, because it had been formed with the military aid of Nazi Germany and Fascist Italy.
Following the 2014 successful synthesis of seaborgium hexacarbonyl, Sg(CO)6, studies were conducted with the stable transition metals of groups 7–9, suggesting that carbonyl formation could be extended to further probe the chemistries of the early 6d transition metals from rutherfordium to meitnerium inclusive. Nevertheless, the challenges of low half-lives and difficult production, make meitnerium hard to access for chemists, though 278Mt and 276Mt are long-lived enough for chemical research and may be produced in the decay chains of 294Ts and 288Mc respectively. 276Mt is likely more suitable, since producing tennessine requires a rare and rather short-lived berkelium target.270Mt, observed in the decay chain of 278Nh with a half-life of 0.69 second, may also be long-lived enough for chemical investigations, though a direct synthesis route leading to this isotope and more precise measurements of its decay properties would be required.
Sources: en.wikipedia.org
== History of ITC == The history of ITC can be traced back to the 1930s when isothermal calorimetry was used to study chemical reactions. In 1965 Christensen and Izatt introduced titration calorimetry as a method for simultaneously determining the equilibrium constant and enthalpy. The ITC technique was then developed by H. D. Johnston in 1968 as a part of his Ph.D. dissertation at Brigham Young University, and was considered niche until introduced commercially by MicroCal Inc. in 1988. In 1978, Beaudette and Langerman conducted one of the earliest calorimetric binding studies using a small volume isoperibol titration calorimeter and a decade later, in 1989, Wiseman, Williston, Brandts, and Lin demonstrated its application in biological systems, marking the beginning of titration calorimetry as a valuable tool for studying biological equilibria. Originally, ITC was most often used to study the binding of small molecules (such as medicinal compounds) to larger macromolecules (proteins, DNA etc.) in a label-free environment. Its application has now broadened, aided by modern improvements, making it possible to measure the heat effects as small as 0.1 μcal (0.4 μJ) and determine the binding constants (K) as high as 108–109 M−1.
=== Cold case review === Every year on the anniversary of the killing, Scotland Yard came under pressure for progress. In the late 1990s, Nickell's murder was re-investigated as part of Operation Enigma, which was a national cross-force investigation into the unsolved murders of 207 women. Under new management, detectives began to collate evidence and files related to the case from 2000. In 2002, ten years after the killing, Scotland Yard used a cold case review team, which used refined DNA techniques only recently made available. A small team of officers and retired veteran investigators analysed statements from witnesses, reassessed files on a number of potential suspects and examined the possibility that the case was linked to other crimes. Officers compared the injuries suffered by Nickell with other attacks and consulted forensic scientists about improvements in DNA matching. In July 2003, reports surfaced that, after 18 months of tests on Nickell's clothes, police had found a male DNA sample which did not match her boyfriend or son. The sample at the time was insufficient to confirm an identity, but was large enough to rule out suspects.
On 12 January 2016, thirty-four past and present Essendon Football Club players – twelve of whom were still on the Essendon list – were suspended until November 2016 after being found guilty of being injected with the banned substance thymosin beta-4 during the 2012 season, significantly compromising Essendon's playing list for 2016. The club received permission to augment its list by recruiting up to ten top-up players from lower levels on contracts which would last until 31 October 2016. The club was limited to players who had been on an AFL list in either 2014 or 2015, with no more than one player to be taken from any state-level club; or, it could recruit any VFL-listed player from its own reserves team without restriction.
A breeder reactor is a nuclear reactor that generates more fissile material than it consumes. These reactors can be fueled with more-commonly available isotopes of uranium and thorium, such as uranium-238 and thorium-232, as opposed to the rare uranium-235 which is used in conventional reactors. These materials are called fertile materials since they can be bred into fuel by these breeder reactors. Breeder reactors achieve this because their neutron economy is high enough to create more fissile fuel than they use. These extra neutrons are absorbed by the fertile material that is loaded into the reactor along with fissile fuel. This irradiated fertile material in turn transmutes into fissile material which can undergo fission reactions. Breeders were at first found attractive because they made more complete use of uranium fuel than light-water reactors, but interest declined after the 1960s as more uranium reserves were found and new methods of uranium enrichment reduced fuel costs. Breeder reactors have been developed and operated in Russia, India, Japan, the United States, France, and China, but only Russia is currently operating a commercial fast breeder reactor as of April 2026.
== Further reading == Ferner S, Koszmagk R, Lehmann A, Heilmann W (1990). "[Reference values of Na(+) and Cl(-) concentrations in adult sweat]". Zeitschrift für Erkrankungen der Atmungsorgane (in German). 175 (2): 70–5. PMID 2264363. Nadel ER, Bullard RW, Stolwijk JA (July 1971). "Importance of skin temperature in the regulation of sweating". Journal of Applied Physiology. 31 (1): 80–7. Bibcode:1971JAPh...31...80N. doi:10.1152/jappl.1971.31.1.80. PMID 5556967. Sato K, Kang WH, Saga K, Sato KT (April 1989). "Biology of sweat glands and their disorders. I. Normal sweat gland function". Journal of the American Academy of Dermatology. 20 (4): 537–63. doi:10.1016/S0190-9622(89)70063-3. PMID 2654204.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.